SCHEMBL4077360

SCHEMBL4077360

COC(=O)c1ccc(CCCNNC(=O)OC(C)(C)C)o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.50
TSHR P16473 1/20 0.48
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
HSP90AA1 P07900 1/20 0.45
ALDH1A1 P00352 4/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 3/20 0.42
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 2/20 0.42
HSD17B10 Q99714 2/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
ALOX12 P18054 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5726306 0.88 HTT (0.52) HTTTSHRNPC1RAB9AHSP90AA1
SCHEMBL15864554 0.77 HTT (0.58) HTTTSHRNPC1RAB9AHSP90AA1
SCHEMBL6620261 0.77 HTT (0.58) HTTTSHRNPC1RAB9AHSP90AA1
SCHEMBL4079236 0.76 CYP4A11 (0.50) TSHRNPC1RAB9AALDH1A1HPGD
SCHEMBL7965253 0.75 HDAC3 (0.55) NPC1RAB9AHPGDKMT2ACYP2D6
SCHEMBL19736942 0.74 HTT (0.67) HTTTSHRNPC1RAB9AHSP90AA1
SCHEMBL4092031 0.73 CA12 (0.46) HTTNPC1RAB9AALDH1A1NPSR1
SCHEMBL5046326 0.73 HTT (0.65) HTTTSHRNPC1RAB9AHSP90AA1
SCHEMBL6619997 0.73 HTT (0.65) HTTTSHRNPC1RAB9AHSP90AA1
SCHEMBL11485462 0.73 HTT (0.65) HTTTSHRNPC1RAB9AHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1847533-B1 SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2013-08-14 EP disclosed
US-7531533-B2 6-Membered heterocyclic compound and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-05-12 US disclosed
EP-1847533-A1 SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF Asahi Kasei Pharma Corporation (JP) 2007-10-24 EP disclosed
US-20070060590-A1 6-Membered heterocyclic compound and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060590-A1 6-Membered heterocyclic compound and use thereof WNT1, CYP11B2, CYP11B1 HTT 4463/4885TSHR 4303/4885NPC1 3052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.